Compare NTLA & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | PRLB |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2016 | 2011 |
| Metric | NTLA | PRLB |
|---|---|---|
| Price | $13.63 | $75.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 2 |
| Target Price | $20.02 | ★ $53.00 |
| AVG Volume (30 Days) | ★ 5.6M | 170.1K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.43 | ★ 33.33 |
| EPS | N/A | ★ 0.33 |
| Revenue | ★ $67,671,000.00 | N/A |
| Revenue This Year | N/A | $8.56 |
| Revenue Next Year | $62.75 | $6.89 |
| P/E Ratio | ★ N/A | $220.12 |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $37.40 |
| 52 Week High | $28.24 | $78.52 |
| Indicator | NTLA | PRLB |
|---|---|---|
| Relative Strength Index (RSI) | 51.20 | 61.54 |
| Support Level | $11.55 | $47.24 |
| Resistance Level | $14.02 | N/A |
| Average True Range (ATR) | 0.94 | 2.47 |
| MACD | 0.11 | -0.22 |
| Stochastic Oscillator | 50.27 | 73.16 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.